Table 1.

In vitro antibacterial and antifungal activities of ciprofloxacin derivatives 2a-j, 5a-i, ciprofloxacin and ketoconazole

Compound	MIC (µg/mL)
	Gram-positive	Gram-negative		Fungi
	S. aureus	E. coli	P. aeruginosa	C. albicans
1	0.70	0.60	1.20	˃100
2a	0.74	0.64	1.12	˃100
2b	0.06	0.18	0.64	15.23
2c	0.67	0.34	1.03	3.89
2d	2.65	4.78	7.25	˃100
2e	0.89	0.53	0.96	2.03
2f	0.94	9.33	3.7	˃100
2g	8	16.98	6.25	˃100
2h	1.2	5.25	3.125	84.21
2i	6.3	4.13	17	. ˃100
2j	1.48	5.13	4.2	˃100
5a	0.36	0.91	1.53	6.23
5b	0.7	0.12	0.19	˃100
5c	0.58	1.03	2.04	2.87
5d	8.14	42.23	12.30	36.12
5e	0.78	0.52	3.25	2.51
5f	4.79	3.89	2.95	˃100
5g	0.28	14.25	23.12	˃100
5h	0.34	0.21	0.49	28.73
5i	0.74	0.63	0.13	˃100
Ciprofloxacin	3.25	0.15	0.22	˃100
Ketoconazole	–	–	–	2.6